Hongzhang Mei

Dr. Hongzhang Mei

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2017 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
FLFengqiao Li
Fengqiao Li
HMHongzhang Mei
Hongzhang Mei
XXXiaodong Xie
Xiaodong Xie
HZHuijuan Zhang
Huijuan Zhang
JLJian Liu
Jian Liu
LJLee Jia
Lee Jia

1 November 2021 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
HMHongzhang Mei
Hongzhang Mei
JWJiping Wang
Jiping Wang
SMShuangge Ma
Shuangge Ma

1 October 2018 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
DXDan Xu
Dan Xu
SLShu-Ting Lu
Shu-Ting Lu
YLYu-Shuang Li
Yu-Shuang Li
ABAju Baidya
Aju Baidya
HMHongzhang Mei
Hongzhang Mei
BWBo Wu
Bo Wu
Background: Gliomas are one of the most common types of primary brain tumors. It is usually evaluated by gadolinium(III)-based contrast agents by magnetic resonance imaging (MRI) in the clinic. Methotrexate (MTX), as a type of folate analog that inhibits the enzyme dihydrofolate reductase, is widely used as a chemotherapeutic agent to treat gliomas in the experiment. Purpose: In this study, a novel theranostic agent MTX-DOTA-Gd (MTX-Gd) was synthesized, which integrates magnetic resonance imaging (MRI) with anticancer treatment. Methods: MTX-Gd was synthesized by connecting MTX and Gd through 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The characterization of MTX-Gd was detected by ultraviolet (UV) and infrared spectroscopy (IR). To confirm the antitumor effect of MTX-Gd, the cytotoxicity of MTX-Gd was examined by the MTT assay. The contrast enhancement of the MTX-Gd was measured through MRI in vitro. Then, nude mice bearing C6 tumor xenografts were used to study in vivo imaging capabilities. Results: The ultraviolet-visible-near infrared radiation (UV-NIR) absorption curve indicated that MTX-Gd had a broad absorption in the region of 500-700 nm. The formation of MTX-Gd was confirmed from the characteristic bands of MTX-DOTA-Gd in the 1413 cm-1 (C-N), 1577 cm-1 (-NH2), and 3429 cm-1 (N-H), in the fourier-transform infrared (FTIR) spectra. MTX-Gd showed little difference in the cell viability compared with MTX, except for the highest concentration (270 μM). In vitro, the imaging of MTX-Gd was significantly brighter than Gd-DOTA at the same concentration, and the brightness and signal intensity of MRI were increased followed by the increased concentration of MTX-Gd. And it also showed that MTX was not visualized on MRI. The other images revealed that the concentration of 4 mM MTX-Gd had the same imaging effect with the concentration of 10 mM Gd-DOTA. Then, MTX-Gd was injected in nude mice bearing C6 tumor xenografts through the tail vein. Significant contrast enhancement was observed at the tumor site from 0.5 h to 3 h. The signal of tumor area was strongest at 3 h due to accumulation by size effect of macromolecules. Conclusion: A novel stable and unique theranostic agent(MTX-Gd) was successfully synthesized, and it has good stability, strong anticancer ability and excellent magnetic capacity. The methotrexate component of MTX-Gd, as a chemotherapeutic agent, played an important role in targeted therapies of cancer. The DOTA-Gd component of MTX-Gd performed as the MRI contrast agent. The superior MRI imaging performance and synergetic chemical antineoplastic ability of MTX-Gd was revealed, and it has great potential in the diagnosis and treatment of glioma and potentially other cancers, with prospects of clinical application in the near future.

31 January 2025 in Journal of Vascular Diseases
Verified
Journal Article
Open access
PDF file
ZIZain Husain Islam
Zain Husain Islam
HMHongzhang Mei
Hongzhang Mei
ZTZoe Tetz
Zoe Tetz
RKRohan Kanchetty
Rohan Kanchetty
SSSophia Stanisic
Sophia Stanisic
BWBowen Wang
Bowen Wang
Abdominal aortic aneurysm (AAA) is a prevalent vascular disease with high mortality rates upon rupture. AAA features a distinct sexual dimorphism, with a prevalence three times higher in males than in females. Interestingly, females are faced with a greater risk of rupture and a worse prognosis following surgical repairs. Nevertheless, stratified approaches for managing and predicting outcomes of AAA in male and female patients remain limited, largely hindered by our incomplete understanding of the mechanisms underlying this sex dimorphism. In this article, we will summarize the recent clinical and preclinical efforts aimed at understanding the therapeutic and mechanistic implications of sex-specific factors shaping AAA.

8 September 2025
Verified
Book Chapter
Open access
PDF file
MZMengxue Zhang
Mengxue Zhang
HMHongzhang Mei
Hongzhang Mei
QZQiong Zhang
Qiong Zhang
Pharmacogenomics (PGx) represents a key step toward personalized chemotherapy for colorectal cancer (CRC) by matching the right patient to the right dose and regimen. This chapter reviews PGx-driven dosing for standard CRC regimens leucovorin/folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and leucovorin/folinic acid, fluorouracil, and irinotecan (FOLFIRI). We outline established PGx biomarkers, such as UGT1A1 and dihydropyrimidine dehydrogenase (DPYD), which have driven Food and Drug Administration (FDA), Clinical Pharmacogenetics Implementation Consortium (CPIC), and European Medicines Agency (EMA) dose-modification recommendations, and then discuss promising, yet investigational, PGx genes, such as TYMS, methylenetetrahydrofolate reductase (MTHFR), GSTP1, and ERCC1. Practical sections cover genotyping platforms, evidence-based dose modification, and EMR-embedded decision support. We conclude with future directions toward polygenic risk scores and multi-omics integration to complete the transition to personalized CRC chemotherapy.

27 August 2026 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
MZMengxue Zhang
Mengxue Zhang
HMHongzhang Mei
Hongzhang Mei
YLYueying Li
Yueying Li
SXShu-Yuan Xiao
Shu-Yuan Xiao
Diversion colitis is an established clinicopathologic complication of fecal stream diversion and may mimic inflammatory bowel disease (IBD) histologically, creating diagnostic and management challenges in the diverted rectum or rectosigmoid colon. We aim to clarify the histologic spectrum of diversion-associated pathology in patients with and without IBD, emphasizing de novo diversion colitis in non-IBD patients and interpretation of chronic colitis patterns in established IBD. We conducted a blinded, rectum‑exclusive histologic comparison of 63 diverted rectal resections (17 non‑IBD, 46 IBD), using a 5‑domain semiquantitative scheme for lymphoid follicles, activity, chronicity, mucosal atrophy, and surface integrity. Reproducibility was assessed by a blinded rereview after a 6-month washout. Ulcerative colitis versus Crohn's disease subgroups were compared by diversion interval-adjusted proportional-odds models with false-discovery rate correction. Available prediversion slides from the IBD group (31/46) were also reviewed for distal margin involvement. Diversion colitis occurred in 3/17 (18%) non‑IBD diverted rectum specimens, while most non‑IBD cases showed diversion change only. In contrast, 43/46 (93%) IBD cases exhibited a chronic colitis pattern, with or without activity, and also higher grades across all 5 parameters than non‑IBD cases. Higher rate of moderate-to-marked chronic active colitis in IBD, together with frequent prediversion distal margin involvement, favors persistent IBD as a likely interpretation in most cases, although severe diversion colitis cannot be definitively excluded by histology alone. Ulcerative colitis cases presented more severe histologic changes of chronic active colitis than those with Crohn's disease. These findings support a context-aware spectrum and practical reporting terminology after clinicopathologic correlation: (i) diversion change, (ii) diversion colitis, and (iii) IBD with superimposed diversion changes.